Hypersensitivity Pneumonitis Market Trends

  • Report ID: 5180
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Hypersensitivity Pneumonitis Market Trends

Growth Drivers

  • Rising Environmental Pollution – It is expected that rise in the release of harmful gases and chemicals into the air is anticipated to drive the growth of hypersensitivity pneumonitis market. Moreover, hypersensitivity pneumonitis is a long illness that is caused by an allergic reaction to certain substances (allergens) inhaled through the air.
    According to estimates, more than 6 million people die from air pollution-related causes worldwide each year.
  • Growing Geriatric Population- Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease (ILD) that is more common among those older than 65 years owing to weekend immune response, and the rising count of older people across the globe is estimated to drive market growth.
    Lately, the number of individuals over 65 in the globe is more than 8% of the population, and this percentage is anticipated to increase to over 15% of the global population by 2050.

Challenges

  • Lack of Awareness – Owing to the absence of sufficient resources in low economic areas people the knowledge about prescription drugs such as corticosteroids is poor. This may impact the market growth as without proper knowledge this medication can be misused.
  • Risk Associated with Underdiagnosis and Misdiagnosis of Hypersensitivity Pneumonitis
  • Side Effects Associated with Long-Term Treatment

Hypersensitivity Pneumonitis Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

6.2%

Base Year Market Size (2023)

USD 1.06 Billion

Forecast Year Market Size (2036)

USD 2.32 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5180
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of hypersensitivity pneumonitis is estimated at USD 1.12 Billion.

The hypersensitivity pneumonitis market size was valued at USD 1.06 Billion in 2023 and is likely to reach USD 2.32 Billion by 2036, registering around 6.2% CAGR during the forecast period i.e., between 2024-2036. Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.

North America is predicted to account for the largest share of 37% by 2036, impelled by increasing spending in healthcare.

Pfizer Inc., Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG, Abbott Laboratories Inc., Astra Zeneca Plc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample